JW Lifescience Corporation

KOSE:A234080 주식 보고서

시가총액: ₩169.4b

JW Lifescience 과거 수익 실적

과거 기준 확인 5/6

JW Lifescience has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 4.6% per year. JW Lifescience's return on equity is 16.3%, and it has net margins of 12.4%.

주요 정보

1.4%

수익 성장률

2.2%

EPS 성장률

Pharmaceuticals 산업 성장11.3%
매출 성장률4.6%
자기자본 수익률16.3%
순이익12.4%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Apr 20
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year

Mar 11
Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year

What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?

Feb 21
What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?

Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?

Feb 02
Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?

We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Jan 12
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

Dec 23
Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 23
Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?

How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?

Nov 27
How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?

수익 및 비용 분석

JW Lifescience 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

KOSE:A234080 수익, 비용 및 수입 (KRW Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 24214,51026,60916,5055,229
31 Mar 24212,20325,61616,1385,229
31 Dec 23206,86028,14415,1005,161
30 Sep 23203,46622,45416,2763,416
30 Jun 23200,05120,72215,9483,416
31 Mar 23195,08717,98914,2124,956
31 Dec 22188,93114,96113,3585,737
30 Sep 22183,11312,13313,3586,289
30 Jun 22175,62413,25011,1397,752
31 Mar 22171,22612,00011,0957,803
31 Dec 21169,81712,91412,9086,242
30 Sep 21170,0395,62313,0525,385
30 Jun 21174,8239,66813,1245,224
31 Mar 21179,65715,90612,9074,971
31 Dec 20183,52117,30013,1805,195
30 Sep 20183,44927,97113,3095,218
30 Jun 20181,52525,08813,5985,058
31 Mar 20175,93723,01513,7664,762
31 Dec 19170,22121,93813,8333,583
30 Sep 19164,79421,36613,7452,922
30 Jun 19161,96421,48512,9382,091
31 Mar 19156,83318,70313,3311,424
31 Dec 18155,23015,82113,6361,249
30 Sep 18154,06914,36313,935968
30 Jun 18151,38813,67113,902730
31 Mar 18148,33114,99712,893488
31 Dec 17143,60016,78312,223399
30 Sep 17139,23416,68111,361524
30 Jun 17133,22315,92211,449606
31 Mar 17133,29915,31411,507602
31 Dec 16132,29015,16211,312665
30 Sep 16129,09615,41611,852536
30 Jun 16129,22314,49611,288498
31 Mar 16127,27214,09710,754454
31 Dec 15125,95012,86410,535399
31 Dec 14111,1219,3579,137342
31 Dec 1388,6141,6337,968396

양질의 수익: A234080 has high quality earnings.

이익 마진 증가: A234080's current net profit margins (12.4%) are higher than last year (10.4%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: A234080's earnings have grown by 1.4% per year over the past 5 years.

성장 가속화: A234080's earnings growth over the past year (28.4%) exceeds its 5-year average (1.4% per year).

수익 대 산업: A234080 earnings growth over the past year (28.4%) exceeded the Pharmaceuticals industry 21.9%.


자기자본 수익률

높은 ROE: A234080's Return on Equity (16.3%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기